← All trials
NCT03789591
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2019
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 116
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CincinnatiLead sponsor
- University of CincinnatiOverall official - principal investigator
- Doris Duke Charitable FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.